Naso-sinus polyposis (PNS) or nasal polyposis is a disease that affects approximately 1 million French people1. It is the most common form of chronic rhinosinusitis2. Of unknown cause although associated with type 2 inflammation in 80% of patients3the disease commonly begins before the age of 30 and is generally diagnosed by an ENT between 40-50 years of age4. In severe forms, the polyps obstruct the sinuses and nasal cavities permanently and sometimes completely, to the point of preventing nasal breathing5. People with PNS may have a continuous runny nose, recurrent severe facial pain that can last for several hours, and be at risk of superinfection.6. Of all the symptoms, loss of smell and taste7 represents a major handicap that can have serious consequences on the quality of life. Some patients declare themselves “blind of the nose”. However, more than 75% of French people do not know what nasal polyposis is, this is revealed by theIfop/Sanofi Genzyme survey8.
A campaign to raise awareness of nasal polyposis and restore hope to patients
Sanofi Genzyme wanted to launch a 3-step awareness campaign, co-signed with the association Anosmia.org, which aims to help people affected by nasal polyposis find appropriate solutions with their doctor. The first stage aims to bring nasal polyposis to the general public, with a focus on olfactory loss (anosmia), its most specific and disabling symptom.9. The second wave aims to make health professionals aware of the handicap represented by olfactory loss. Finally, the third part of this campaign, more specific, helps the patient to better understand the symptoms of nasal polyposis and to engage in dialogue with his specialist doctor.
Find this campaign on social networks reinforced with the hashtag #SeSentirVivre and find answers to your questions about nasal polyposis on the site www.polypose-nasale.fr.
On the occasion of the Top Health Awards, we award a Public Favorite Award. Want to vote for the Nasal Polyposis Campaign? It’s this way !
Sources:
1: Klossek JM, Neukirch F, Pribil C, et al. Prevalence of nasal polyposis in France: a cross-sectional, case–control study. Allergy 2005; 60: 233-237
2: Fokkens, WJ, Lund, V., Bachert, C., et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. allergy. 2019
3: Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-478
4: Bonfils et al, Nasosinus polyposis. Chronic rhinosinusitis with polyps, EMC Oto rhino laryngologie 2017, 20 435 A 10
5: Fokkens WJ, Lund, VJ, Hopkins C., et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology.2020;S29:1-464.
6: Fokkens WJ, Lund, VJ, Hopkins C., et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology.2020;S29:1-464.
7: Bonfils et al, Nasosinus polyposis. Chronic rhinosinusitis with polyps, EMC Oto rhino laryngologie 2017, 20 435 A 10
8: Ifop / Sanofi Genzyme study carried out by an online self-administered questionnaire from February 5 to 10, 2021, among a sample of 3,013 people, from the French population aged 18 and over, residing in metropolitan France
9: Bonfils et al, Nasosinus polyposis. Chronic rhinosinusitis with polyps, EMC Oto rhino laryngologie 2017, 20 435 A 10
Article produced in partnership with Sanofi Genzyme.
7000035636 – 10/2021